MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

M Østergaard,H Bliddal,M Rell-Bakalarska,M Sejer Hansen,F Staelens,J W J Bijlsma,A Dudek,C Schaufelberger,B Sundman-Engberg,L T H Jacobsson,R Haake

doi:10.1136/annrheumdis-2014-206359

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

M Østergaard, H Bliddal + Show 9 more

Open Access

PDF Available

https://doi.org/10.1136/annrheumdis-2014-206359

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases	Publication Date: Dec 15, 2014
Citations: 28	License type: open-access

Affiliation: Glostrup Hospital, Frederiksberg Hospital, Gentofte Hospital, UCB Pharma (Belgium), University Medical Center Utrecht, University of Gothenburg, UCB Pharma (United States)

#Certolizumab Pegol #Bone Erosion Score #Synovitis Scores #Certolizumab Pegol Group #Certolizumab Pegol In Rheumatoid Arthritis #Osteitis Scores #Disease-modifying Antirheumatic Drug Therapy #Baseline Synovitis #Rheumatoid Arthritis #Bone Oedema

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

ObjectivesTo identify the first time point of an MRI-verified response to certolizumab pegol (CZP) therapy in patients with rheumatoid arthritis (RA).MethodsForty-one patients with active RA despite disease-modifying antirheumatic drug therapy...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16